Morningstar

BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting

SAN DIEGO, Nov. 15, 2025 /PRNewswire/ -- BrainXell, Inc. today announced that data will be presented during poster sessions at the 2025 Society for Neuroscience (SfN) Annual Meeting in San Diego, ...
Nasdaq

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting

Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell ...
Nasdaq

Fate Therapeutics to Present Clinical and Preclinical Data on Off-the-Shelf iPSC-Derived Cell Therapies at EULAR 2025

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
Morningstar

BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease

SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- BrainXell Therapeutics today announced the disclosure of its first scientific data, which will be presented at two conferences this month: the Cell Symposia | ...
WDAF-TV

Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

LONDON, Ontario, March 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract ...